1. Introduction {#sec1}
===============

Cholesterol gallstone disease is one of the most prevalent and most costly digestive diseases requiring hospital admission, since its prevalence ranges from 10% to 15% in adults. Medical expenses for gallstone treatment exceeded \$4 billion in facility charges in 2004 in the United States \[[@B1]\] and rise to \$6.5 billion when surgical complications occur \[[@B2]\]. The formation and growth of cholesterol gallstones, which accounts for 75% of the gallstones in westernized countries \[[@B3]--[@B5]\], are secondary to abnormal cholesterol homeostasis \[[@B6]\]. Of note, the main risk factors for cholesterol gallstone disease (e.g., obesity, type 2 diabetes, dyslipidemia, and hyperinsulinemia) are also well-known components of the metabolic syndrome \[[@B7]--[@B11]\], supporting the hypothesis that gallstone disease is just another component of the metabolic syndrome \[[@B12]--[@B14]\] ([Table 1](#tab1){ref-type="table"}). Due to the high prevalence of the metabolic syndrome, it has been suggested that the phenotype of cholesterol gallstones may result from the interaction between insulin resistance, genetic factors, and a number of environmental factors \[[@B15]\]. A series of gallstone (*LITH*) genes have been identified, which affect cholesterol homeostasis and promote cholesterol gallstone formation and growth \[[@B15]\]. Also, a strong interest has developed to investigate the epigenetic mechanisms that are able to influence gene expression in the absence of an altered DNA sequence \[[@B16]\], in response to several environmental stimuli \[[@B15]\].

A comprehensive analysis of these latter aspects as key factors in linking cholesterol homeostasis to gene expression and to the environment might provide a clue for both the prevention of gallstone formation in subjects at risk and future therapeutic approaches via manipulation of cholesterol homeostasis.

2. Cholesterol Homeostasis and the Formation of Cholesterol Gallstones {#sec2}
======================================================================

2.1. Multifactorial Contributions to the Pathogenesis of Gallstones {#sec2.1}
-------------------------------------------------------------------

Precipitation of excess cholesterol in bile as solid plate-like monohydrate crystals is a prerequisite for the formation of cholesterol gallstones \[[@B17], [@B18]\]. It is evident that all factors contributing to cholesterol homeostasis (i.e., intestinal cholesterol absorption, hepatic cholesterol biosynthesis, biliary output, and cholesterol conversion to bile acids) play a vital role in the pathogenesis of cholesterol gallstones. In fact, specific pathogenic factors concurring to the formation of cholesterol gallstones in humans must include hepatic hypersecretion of cholesterol into bile leading to a supersaturated bile, accelerated cholesterol nucleation/crystallization, defective gallbladder motility (a form of cholesterol-induced leiomyopathy leading to gallbladder stasis \[[@B6], [@B19], [@B20]\]), increased absorption of intestinal cholesterol, and *LITH* gene expression \[[@B21], [@B22]--[@B28]\] ([Figure 1](#fig1){ref-type="fig"}).

2.2. Liver, Bile, Intestine, Gene Expression, and Cholesterol Homeostasis {#sec2.2}
-------------------------------------------------------------------------

The liver plays a central role in cholesterol homeostasis and lipoprotein metabolism since it is mainly involved in synthesis and catabolism of cholesterol and lipoproteins and is the exclusive excretory route for cholesterol from the body \[[@B20]\].

In normal subjects with an extremely low dietary cholesterol intake (*∼*30 mg/day, pure vegetarians), biliary cholesterol mainly derives from *de novo* synthesis \[[@B29]\]. In the physiological steady state, hepatic secretion of biliary cholesterol principally derives from newly synthesized cholesterol, plasma lipoproteins (the main source of biliary cholesterol is HDL cholesterol, as mainly suggested by animal models \[[@B30]--[@B33]\]), and intestinal absorption of cholesterol. Dietary and reabsorbed biliary cholesterol is delivered by the enterolymphatic circulation to the liver for resecretion into bile. As demonstrated by both human and animal studies, reabsorption of biliary cholesterol by the enterocytes has different absorption efficiency \[[@B34], [@B35]\] and depends on sterol transport proteins compared to dietary cholesterol \[[@B36]--[@B38]\]. Intestinal absorption of cholesterol is a multistep process regulated by multiple genes \[[@B37]\], which is determined by the balance between influx and efflux of intraluminal cholesterol molecules crossing the brush border membrane of the enterocyte \[[@B37]\].

The rate of whole-body cholesterol synthesis by the liver is approximately 8--10 mg/day/kg body weight in humans \[[@B39]\], and, under normal physiological conditions, *de novo*synthesis contributes to biliary cholesterol secretion approximately by 15% \[[@B40]--[@B43]\]. Interestingly, cholesterol synthesis by the liver is suppressed by a negative feedback regulatory mechanism through the sterol regulatory elementary binding protein-1 (SREBP-1) pathway when dietary cholesterol intake is increased, which also induces an enhanced secretion of cholesterol into bile, the conversion of cholesterol into bile acids (subsequently for secretion into bile), an increased cholesterol esterification and storage, and an enhanced lipoprotein secretion into the circulation \[[@B20]\]. In humans, the fibroblast growth factor receptor 4 (FGFR4) may have an effect on maintaining bile acid homeostasis by regulating the expression of cholesterol 7alpha-hydroxylase (CYP7A1), the rate-limiting enzyme for the classic pathway of bile acid biosynthesis \[[@B44]\]. Additionally, the liver X receptor (LXR) plays a main role in cholesterol homeostasis because it can activate the transcription of the genes, such as ABCG5/8, ABCA1, and ABCG1, involved in the response to excess cholesterol intake \[[@B45]--[@B47]\]. In mice, it has been reported that there is an increased propensity to cholesterol crystallization and gallstone formation in bile following the activation of hepatic LXR and direct upregulation of the major cholesterol efflux transporters ABCG5 and ABCG8 on the canalicular membrane of hepatocyte \[[@B48]\].

2.3. Altered Cholesterol Homeostasis: The Lithogenic State {#sec2.3}
----------------------------------------------------------

Pathologic conditions linked to cholesterol gallstone formation in humans are characterized by a "lithogenic state," in which the *de novo*synthesis could provide the liver with more cholesterol for secretion into bile. The current view on the physical chemistry of cholesterol carriers in bile is summarized in [Figure 2](#fig2){ref-type="fig"}. Bile contains the three classes of biliary lipids (i.e., bile acids, phospholipids, and cholesterol), and specific cholesterol carriers in health include simple and mixed micelle and small and large vesicles. Sustained cholesterol supersaturation in bile will lead to a cascade of events in which excess cholesterol will lead to nucleation and crystallization and finally precipitate as solid plate-like monohydrate crystals, the first key step in cholesterol gallstone formation.

Bile becomes desaturated with cholesterol after long-term administration of statins, the competitive inhibitors of HMG-CoA reductase, and the rate-limiting enzyme in cholesterol biosynthesis \[[@B49]--[@B56]\].

Compared to gallstone-resistant AKR mice, susceptible C57L mice on the lithogenic diet still display higher HMG-CoA reductase activities together with lower activities of both bile acid synthetic enzymes cholesterol 7*α*-hydroxylase and sterol 27-hydroxylase \[[@B57]\]. Furthermore, higher HMG-CoA reductase activities have been found in gallstone patients compared with control subjects \[[@B58]--[@B61]\]. This evidence underscores the role of *de novo* cholesterol synthesis in the formation of lithogenic bile in humans at risk for gallstones.

The small intestine also plays a key role in the absorption of both dietary and biliary cholesterol, which is present in bile solely in the unesterified form (at least 97% of total sterols in bile) \[[@B15]\].

The importance of the gallbladder on the regulation of reabsorption of biliary cholesterol has been underlined by an animal model showing that the gallbladder can modulate the physical states of cholesterol, which may in turn influence the intestinal absorption of biliary cholesterol. In this model, crystallized bile markedly reduced cholesterol uptake and absorption by the enterocyte \[[@B38]\].

The average intake of cholesterol in the western diet is approximately 300--500 mg per day (predominantly animal origin). The small intestine contains both unesterified and esterified cholesterol, with the latter usually in small proportion \[[@B62]\]. Any cholesteryl ester entering the intestine must be hydrolyzed by pancreatic cholesterol esterase in order to be absorbed. Bile delivers 500--2400 mg of cholesterol per day to the intestine \[[@B63]\], and this amount is approximately two to three times the dietary cholesterol. An additional source of intraluminal cholesterol (about 300 mg of cholesterol per day) comes from the turnover of intestinal mucosal epithelium \[[@B37]\]. It has been demonstrated that intestinal factors have a major role in the pathogenesis of mouse gallstone formation \[[@B64]\], since the deficiency of cholesterol esterification in the intestine of ACAT2 knockout mice leads to a marked reduction in intestinal cholesterol absorption and complete resistance to diet-induced cholesterol gallstones.

Additionally, the lack of expression of intestinal Apo-B48 (but not Apo-B100) leads to a significant reduction in biliary cholesterol secretion and gallstone formation, possibly by decreasing intestinal absorption and hepatic bioavailability of cholesterol \[[@B65]\]. Apo-E knockout mice on the lithogenic diet show reduced biliary cholesterol secretion and gallstone prevalence, possibly due to a decreased availability of chylomicron-derived cholesterol in the liver for biliary cholesterol secretion \[[@B66]\]. Although results from animal studies underscore the role of cholesterol derived from the intestine on biliary cholesterol secretion and provide clear evidence that high dietary cholesterol through this pathway enhances cholelithogenesis, human studies concerning this topic gave conflicting results. It has been demonstrated that biliary cholesterol saturation increases with increasing cholesterol intake, inducing the formation of lithogenic bile and solid cholesterol crystals in some subjects \[[@B67]\]. Conversely, a group of 9 healthy women showed no increase in biliary cholesterol saturation after a high-cholesterol diet \[[@B68]\], and 6 normolipidemic women and 6 hyperlipidemic patients without gallstones showed no change in biliary cholesterol saturation when dietary cholesterol was increased from 300 mg to 1,500 mg daily \[[@B69]\]. An increase in biliary cholesterol saturation with modest increments in dietary cholesterol has been noticed in a group of 12 patients with asymptomatic gallstones (six men and six women), as compared with 7 healthy women (the diets containing 500, 750, and 1,000 mg of cholesterol daily for 3-week periods in random sequence). Interestingly, the biliary cholesterol saturation increased in this study group independently from the presence of gallstones \[[@B70]\]. Results from this study showed that women with gallstones had higher biliary cholesterol saturation than normal women at corresponding levels of cholesterol consumption, and six of the seven normal women formed lithogenic bile when ingesting a diet containing 1,000 mg of cholesterol. The discrepancies in human studies might be explained, at least in part, by differences in population sampling, by dissimilar diets, and by variations in the absorption efficiency of intestinal cholesterol.

3. Genetic, Epigenetic, and Environmental Factors {#sec3}
=================================================

The analysis of the mechanisms linking environmental factors to the genes in the determination of human health is of importance in the field of life sciences and biomedical research. Several studies have demonstrated that family history, genetics, dietary, and cultural habits have a main role in the onset of gallstones \[[@B71]--[@B73]\]. Furthermore, a number of observations have found that a complex genetic basis could play a key role in determining individual predisposition to develop cholesterol gallstones in response to environmental factors \[[@B22], [@B23], [@B26], [@B28]\], and a wide spectrum of environmental and genetic risk factors may influence the onset of gallstone disease in humans \[[@B74], [@B75]\]. The analysis of twin pairs from The Swedish Twin Registry showed that genetic factors are estimated to account for about 25% of gallstone risk \[[@B76]\] and that twins carrying a heterozygous or homozygous ABCG8 D19H genotype have a significantly increased risk of gallstone disease \[[@B77]\]. The *ABCG8*p.D19H may lead to lower intestinal cholesterol absorption, lower serum cholesterol levels, and higher hepatic cholesterol synthesis, and polymorphisms in the ABCG5/ABCG8 genes are certainly related to the variations in plasma lipid levels, cholesterol saturation of bile \[[@B78]\], and insulin resistance \[[@B79]\]. An inventory of human cholesterol gallstone (*LITH*) genes has been depicted \[[@B15]\], and this list is rapidly growing. It has been recently suggested that susceptibility to gallstone disease may be influenced in humans by mucin gene polymorphisms \[[@B80]\] or FGFR4 polymorphism \[[@B44]\] and that the mucin-like protocadherin gene (MUPCDH) polymorphism rs3758650 has been considered a genetic marker to predict symptomatic gallstone disease \[[@B81]\]. Furthermore, carriers of CG genotype of ABCG8 rs11887534 showed higher risk of gallstones, as well as gallbladder and bile duct cancer compared with carriers of the GG genotype \[[@B82]\].

On the other hand, besides genes, the role of epigenetics has been highlighted by a number of human studies as the key factor in the onset of several chronic metabolic \[[@B83]--[@B88]\] and nonmetabolic diseases, such as cancer \[[@B89]--[@B91]\] cardiovascular diseases \[[@B92]\], neurodegenerative diseases \[[@B93]\], and birth defects \[[@B94]\], as a consequence of exposure to "toxic" agents occurring *in utero*before birth \[[@B16], [@B95]\]. They occur when the function of a gene is altered by various mechanisms, although its DNA sequence remains stable \[[@B16]\]. Transgenerational effects and fetal programming result from a mother\'s exposure and are inherited through successive generations in the absence of direct exposure of the offspring. Fetal programming, in turn, results in the onset of diseases in adult age, underlying the importance of developmental factors in influencing the risk of later-life disease \[[@B96]\]. Diet \[[@B97], [@B98]\] or environmental exposition to a number of chemical agents like heavy metals (e.g., cadmium, arsenic, nickel, chromium, and methylmercury) \[[@B99]--[@B103]\], air pollutants (e.g., particulate matter, black carbon, and benzene), and endocrine-disrupting/reproductive toxicants (e.g., diethylstilbestrol, bisphenol A, persistent organic pollutants, dioxin, and pesticides \[[@B104]--[@B108]\]) are able to induce epigenetic changes (mainly DNA methylation, histone acetylation/deacetylation \[[@B109]\], and noncoding microRNAs) \[[@B110], [@B111]\], which are involved in a wide range of metabolic diseases including obesity \[[@B86], [@B112]\], abnormal hepatic triglyceride accumulation \[[@B87]\], and the metabolic syndrome \[[@B88], [@B113]\], type 2 diabetes \[[@B83]--[@B85]\], all well-known risk factors for gallstone disease and mainly attributable to insulin resistance. Interestingly, it has been recently reported by a cluster of analyses a significant association of gallbladder diseases with environmental pollutants (heavy metals) in drinking water \[[@B114]\].

The interaction of histone acetyltransferases (HATs) and histone deacetylases (HDACs) and histones strongly affects gene transcription, and, in particular, it has been suggested that HDACs are important in the regulation of lipid homeostasis \[[@B109]\]. Of note, microRNAs (miR-122, miR-370, and miR-33) have a major influence on cholesterol homeostasis. They are important posttranscriptional regulators of gene expression \[[@B115]--[@B117]\] and strongly affect cholesterol metabolism \[[@B118]\]. It has been recently reported by an animal model that maternal low-protein diet during gestation and lactation significantly alters cholesterol homeostasis in weaning piglets through altered epigenetic regulation (promoter hypomethylation, decreased histone H3, H3 lysine 9 monomethylation, H3 lysine 27 trimethylation, and increased H3 acetylation) of the *HMGCR*(the rate-limiting enzyme in cholesterol biosynthesis) and *CYP7A1*(the rate-limiting enzyme for conversion of cholesterol to bile acids) genes, with possible long-term consequences in cholesterol homeostasis later in adult life \[[@B97]\]. In the rat, maternal undernutrition leads to long-term dysregulation of cholesterol metabolism in the offspring through epigenetic mechanisms \[[@B98]\].

In humans, it has been reported that placental insufficiency-induced intrauterine growth restriction secondary to adverse events *in utero* may be responsible for metabolic events leading to the metabolic syndrome \[[@B98], [@B119], [@B120]\].

The bile acid receptor farnesoid X receptor (FXR) is currently considered to be the intracellular "sensor" of bile acids \[[@B121], [@B122]\]. Cells synthesize oxysterols under conditions of cholesterol overload, and oxysterols in turn bind and activate LXR, which acts to reduce systemic cholesterol burden \[[@B121]--[@B123]\]. FXR is highly expressed in the enterohepatic system and regulates the expression of the genes involved in the maintenance of cholesterol, bile acid, and triglyceride homeostasis \[[@B124]\]. Of note, it has been recently suggested by a comparison of genomic FXR-binding sites in healthy control and obese mice that FXR transcriptional signaling is altered in diet-induced obese mice, which may underlie aberrant metabolism and liver function in obesity \[[@B125]\].

In conclusion, frequent metabolic abnormalities such as atherosclerosis, obesity, metabolic syndrome, and gallstone disease are related to impaired cholesterol homeostasis. The current view that such abnormalities gain clinical relevance only during adulthood and elderly age is dramatically changing. Both genetic and epigenetic studies suggest a very early onset of chronic disease already *in utero*. Epigenetic mechanisms underlying such developmental events are still under investigation, in particular in the case of cholesterol homeostasis and gallstone disease. Starting from these particular metabolic conditions, a better understanding of mechanisms resulting in chromatin remodeling in response to environmental stimuli acting on the epigenome may offer new options for therapy of cholesterol cholelithiasis and better possibilities for primary prevention in subjects at risk.

ABC:

:   ATP-binding cassette (transporter)

NPC1L1:

:   Niemann-Pick C1-like 1 protein.  Adapted from de Bari et al. \[[@B127]\],  Wang et al.  \[[@B20]\], and Portincasa and Wang  \[[@B6]\].

![Current view on the complex interplay of pathogenic factors in cholesterol gallstone formation. The combination of multiple disturbances affecting cholesterol homeostasis in bile is essential for cholesterol gallstone formation. *LITH* genes and genetic defects play a crucial role in the formation of cholesterol gallstones. A large number of *LITH* genes have been identified in mouse models of cholesterol gallstones, and based on mouse studies, several human *LITH* genes have been identified, and their contributions to the formation of cholesterol gallstones are now being investigated. Hepatic hypersecretion of biliary cholesterol leads to unphysiological supersaturation of gallbladder bile with cholesterol. At the enterocyte (small intestine) level, absorption of cholesterol is enhanced via the Niemann-Pick C1-like 1 (NPC1L1) pathway. In bile, as a consequence, accelerated phase transitions of cholesterol occur, which are facilitated by prolonged gallbladder stasis due to impaired gallbladder motility and immune-mediated gallbladder inflammation, as well as hypersecretion of mucins and accumulation of mucin gel in the gallbladder lumen \[[@B6], [@B21]\]. In bile, growth of solid plate-like cholesterol monohydrate crystals to form gallstones is a consequence of persistent hepatic hypersecretion of biliary cholesterol together with enhanced gallbladder mucin secretion and incomplete evacuation by the gallbladder due to its impaired motility function \[[@B6], [@B126]\]. The two inlets on the left depict the major pathways of cholesterol absorption and secretion at the enterocyte level and at the hepatocyte level, respectively, as mediated by specific transporter proteins. Also, relative cholesterol hypersecretion into hepatic bile may or may not be accompanied by normal, high, or low secretion rates of biliary bile acids or phospholipids. Although NPC1L1 is expressed in the liver, its mRNA expression and protein concentrations are very low compared to those in the small intestine, thereby suggesting that hepatic NPC1L1 could have a minor role in regulating biliary cholesterol secretion.](CHOL2013-298421.001){#fig1}

![(a) The figure shows the physical states of lipids in human bile \[[@B20]\]. Bile is composed mainly of water (more than 90%) \[[@B128]\]. Bile acids are highly soluble, while cholesterol and phospholipids are highly insoluble in water. In bile, bile acids are found as monomers up to the critical micellar concentration (*≈*1--3 mM), a cut-off value after which bile acids can self-aggregate as simple micelles, binding a molecule of cholesterol. This step leads to increased aqueous solubility of cholesterol. Phospholipids in an aqueous environment can self-aggregate to form stable bilayer vesicles containing also a trace amount of bile acids, if any. A large amount of the cholesterol molecules is inserted into these bilayers of vesicles between the hydrophobic acyl chains of phospholipids. With typical gallbladder lipid concentrations and compositions, simple bile acid and mixed bile acid-lecithin micelles coexist in a ratio of 1 : 5. Unilamellar vesicles are larger spherical carriers in which even more cholesterol is solubilized into the bilayers of phospholipids. The ratio of unilamellar vesicles to micelles depends on the bile acid and phospholipid concentrations of bile, which is the greatest in bile with low bile acid and high phospholipid concentrations. Furthermore, at low bile acid concentrations and high phospholipid concentrations, these biliary phospholipids often form large multilamellar layers of vesicles. High concentrations of bile acids can dissolve these vesicles to form mixed micelles. (b) The picture depicts the ternary bile salt-cholesterol-phospholipid phase diagram in which the different pathways of cholesterol solubilization and/or precipitation in bile are shown \[[@B21]\]. The concentrations of three biliary lipids (bile acids, cholesterol, and phospholipids) are shown as percentages on the three axes of the triangle with a total lipid concentration of 7.2 g/dL, pH 7, and a temperature of 37°C \[[@B129], [@B130]\]. Different zones occupying areas within the triangle are shown, with each one containing different cholesterol carriers. The one-phase (*φ*) zone under the saturation curve contains only micelles and represents the bile being unsaturated with cholesterol. Above, three other zones exist with cholesterol supersaturation: a right two-phase (R 2-*φ*) zone containing saturated micelles and vesicles; a central three-phase (C 3-*φ*) zone containing saturated micelles, vesicles, and solid cholesterol crystals; and a left two-phase (L 2-*φ*) zone containing saturated micelles and solid cholesterol crystals. Whereas cholesterol precipitation is rapid in case of excess bile acids, at increasing amounts of phospholipids, cholesterol may reside in vesicles with phospholipids. At this moment, solid cholesterol crystal formation is slower or absent. Cholesterol crystallization, the first key step in cholesterol gallstone disease, is increasing at increasing concentrations of cholesterol, in the central and left zones, above the "safe" and physiological micellar zone.](CHOL2013-298421.002){#fig2}

###### 

Major risk factors for cholesterol gallstones.

  --------------------------------------------
  Independent
   (i) Increasing age
   (ii) Female gender
   (iii) Race
   (iv) Family history
  Dietary
   (i) High calorie
   (ii) High cholesterol
   (iii) High fat
   (iv) High *trans*-fatty acids
   (v) Low fiber
   (vi) Low *cis*-unsaturated fats
   (vii) High refined carbohydrates
  Life style
   (i) Low grade physical activity
   (ii) Prolonged fasting
   (iii) Rapid weight loss
   (iv) Pregnancy and parity
   (v) Oral contraceptives
   (vi) Estrogen replacement therapy
  Associated conditions
   (i) The metabolic syndrome
   (ii) Obesity
   (iii) Insulin resistance
   (iv) Diabetes type 2
   (v) Nonalcoholic fatty liver disease
   (vi) Gallbladder and/or intestinal stasis
  --------------------------------------------

Adapted and modified from Portincasa et al. The Lancet, 2006 \[[@B21]\].
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